文献速递细菌感染、耐药与抗菌药物

血管内金黄色葡萄球菌接种量增加是菌血症患者血清IL-10升高与死亡率之间的关联

Increased Endovascular Staphylococcus aureus Inoculum Is the Link Between Elevated Serum Interleukin 10 Concentrations and Mortality in Patients With Bacteremia.
PubMed 文献 · Clin Infect Dis · 2017-01-01

该研究纳入133例连续金黄色葡萄球菌菌血症患者,发现死亡组血清IL-10中位数显著高于存活组,高IL-10患者血管内感染源更常见且菌血症水平更高,体外实验显示高接种量诱导更多IL-10,提示高菌量驱动IL-10抗炎反应预示不良预后。

要点

  • 菌血症死亡组血清IL-10中位数36.0 pg/mL显著高于存活组10.4 pg/mL。
  • 高IL-10患者菌血症水平更高(中位35.5 vs 0.5 CFU/mL)。
  • 临床可考虑以IL-10作为初始生物标志物,对高危患者更积极抗菌以快速降低菌量。

核心结论

  • 金黄色葡萄球菌菌血症临床呈现时血清IL-10升高与死亡率高度相关。
  • 高菌血症水平驱动的高血管内肽聚糖浓度是IL-10抗炎反应的关键介质,预示不良临床结局。

研究设计与样本

  • 收集133例连续金黄色葡萄球菌菌血症患者的血液和分离株。
  • 采用电化学发光法检测血清IL-10,并用磁珠细菌捕获法测定高IL-10组(n=8)与低IL-10组(n=8)患者血清中的细菌接种量。
  • 将两组金黄色葡萄球菌引入全血进行体外实验,以确定不同接种量下的IL-10产生。

主要发现

  • 死亡组(n=27)血清IL-10中位数36.0 pg/mL,存活组(n=106)为10.4 pg/mL,P < .001。
  • 高IL-10患者更常见血管内感染源。
  • 高IL-10组菌血症接种量中位数35.5 CFU/mL,低IL-10组为0.5 CFU/mL,P = .044。
  • 体外实验显示108 CFU/mL产生的IL-10高于103 CFU/mL(4.4 ± 1.8 vs 1.0 ± 0.6 pg/mL,P < .01)。

临床怎么用

  • 临床可考虑以IL-10作为初始生物标志物,识别高危金黄色葡萄球菌菌血症患者。
  • 对高风险患者可考虑更积极的抗菌药物治疗以快速降低细菌负荷。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cell wall peptidoglycan stimulates interleukin 10 (IL-10) production in Staphylococcus aureus bacteremia (SaB) animal models, but clinical data are not available. This study evaluates the impact of intravascular bacterial cell numbers (ie, the level of bacteremia), in patients at the time of clinical presentation on IL-10 production and its association with S. aureus bacteremia (SaB) mortality. METHODS: Blood and isolates were collected in 133 consecutive SaB patients. Serum IL-10 was quantified by an electrochemoluminescence assay. Bacterial inoculum was measured in patient sera with elevated (n = 8) or low (n = 8) IL-10 using a magnetic bacterial capture assay. Staphylococcus aureus from these 2 groups were introduced into whole blood ex vivo to determine IL-10 production with variable inocula. RESULTS: IL-10 serum concentration was higher in SaB patient mortality (n = 27) vs survival (n = 106) (median, 36.0 pg/mL vs 10.4 pg/mL, respectively, P < .001). Patients with elevated IL-10 more often had endovascular SaB sources. The inoculum level of SaB was higher in patients with elevated serum IL-10 vs patients with low IL-10 (35.5 vs 0.5 median CFU/mL; P = .044). Ex vivo studies showed that 108 CFU/mL yielded greater IL-10 than did 103 CFU/mL (4.4 ± 1.8 vs 1.0 ± 0.6 pg/mL; P < .01). CONCLUSIONS: Elevated IL-10 serum concentrations at clinical presentation of SaB were highly associated with mortality. High intravascular peptidoglycan concentration, driven by a higher level of bacteremia, is a key mediator of IL-10 anti-inflammatory response that portends poor clinical outcome. Using IL-10 as an initial biomarker, clinicians may consider more aggressive antimicrobials for rapid bacterial load reduction in high-risk SaB patients.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Rose WE, Shukla SK, Berti AD, et al. Increased Endovascular Staphylococcus aureus Inoculum Is the Link Between Elevated Serum Interleukin 10 Concentrations and Mortality in Patients With Bacteremia. Clin Infect Dis. 2017. PMID: 28205673. doi:10.1093/cid/cix157

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。